超声引导下经皮冷冻消融配合全雄激素阻断治疗前列腺癌的临床效果及对患者免疫功能的影响

doi:10.3969/j.issn.1671-7171.2022.10.031

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1128 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨超声引导下经皮冷冻消融术联合全雄激素阻断治疗前列腺癌的临床效果及对患者免疫功能的影响。【方法】回顾性分析2013年2月至2016年2月本院收治的78例前列腺癌患者的临床资料,根据治疗方案的不同将其分为观察组(n=40)和对照组(n=38)。对照组给予全雄激素阻断治疗,观察组在对照组基础上行超声引导下经皮冷冻消融术治疗。比较两组治疗前、治疗后6个月血清前列腺特异性抗原(PSA)、游离前列腺抗原(fPSA)、人前梯度蛋白2(AGR2)以及免疫功能指标(CD3⁺、CD4⁺、CD4⁺/CD8⁺)、扩展性前列腺癌复合指数量表(EPIC)评分,并统计术后2年、3年、5年生存情况。【结果】观察组治疗后6个月血清PSA、fPSA、AGR2水平均低于对照组,血清CD3⁺、CD4⁺、CD4⁺/CD8⁺水平均高于对照组(P<0.05);观察组治疗后6个月EPIC评分均高于对照组(P<0.05)。两组术后2年、3年生存率相比,差异无统计学意义(P>0.05),观察组术后5年生存率高于对照组,差异有统计学意义(P<0.05)。【结论】超声引导下经皮冷冻消融术联合全雄激素阻断治疗前列腺癌可降低血清PSA、fPSA、AGR2水平,可改善患者免疫功能及生活质量,提高生存率,值得临床借鉴。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张鹏飞
	雷毅
	薛菁

关键词 ：前列腺肿瘤, 冷冻外科手术, 超声检查, 雄激素拮抗药

Abstract：【Objective】 To investigate the clinical effect of ultrasound guided percutaneous cryoablation combined with total androgen blockade in the treatment of prostate cancer and its influence on patients' immune function. 【Methods】 The clinical data of 78 patients with prostate cancer admitted to our hospital from February 2013 to February 2016 were analyzed retrospectively, and they were divided into the observation group (n=40) and the control group (n=38) according to different treatment schemes. The control group was treated with total androgen blockade, and the observation group was treated with ultrasound guided percutaneous cryoablation on the basis of the control group. The serum prostate specific antigen (PSA), free prostate antigen (fPSA), human pregradient protein 2 (AGR2), immune function indicators (CD3⁺, CD4⁺, CD4⁺/CD8⁺), and expanded prostate cancer composite index (EPIC) scores were compared between the two groups before treatment and 6 months after treatment, and the survival conditions of 2, 3, and 5 years after operation were calculated. 【Results】 The levels of serum PSA, fPSA, AGR2 in the observation group were lower than those in the control group 6 months after treatment, and the levels of serum CD3⁺, CD4⁺, CD4⁺/CD8⁺ were higher than those in the control group (P<0.05); EPIC scores in the observation group were higher than those in the control group 6 months after treatment (P<0.05). There was no significant difference in the 2-year and 3-year survival rates between the two groups (P>0.05). The 5-year survival rate in the observation group was higher than that in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Ultrasound guided percutaneous cryoablation combined with total androgen blockade can reduce the serum PSA, fPSA, AGR2 levels, improve the immune function and quality of life of patients with prostate cancer, and improve the survival rate, which is worthy of clinical reference.

Key words： Prostatic Neoplasms Cryosurgery Ultrasonography Androgen Antagonists

收稿日期: 2021-09-15

中图分类号:

R737.25

通讯作者: *E-mail:xj13892980530@163.com

引用本文:

张鹏飞, 雷毅, 薛菁. 超声引导下经皮冷冻消融配合全雄激素阻断治疗前列腺癌的临床效果及对患者免疫功能的影响[J]. 医学临床研究, 2022, 39(10): 1553-1556.
ZHANG Peng-fei, LEI Yi, XUE Jing. Clinical Effect of Ultrasound Guided Percutaneous Cryoablation Combined with Total Androgen Blockade in the Treatment of Prostate Cancer and its Influence on Patients' Immune Function. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1553-1556.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.10.031 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I10/1553

[1] 沈志远,陶晶,徐骏,等.转移性去势抵抗性前列腺癌多西他赛/泼尼松治疗失败后加用雌二醇氮芥的疗效和安全性:单中心回顾性研究[J].临床泌尿外科杂志,2020,35(3):15-18.
[2] AHDOOT M,WILBUR A R,REESE S E,et al.MRI-targeted,systematic,and combined biopsy for prostate cancer diagnosis[J].N Engl J Med,2020,382(10):917-928.
[3] MATEO J,PORTA N,BIANCHINI D,et al.Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations(TOPARP-B):a multicentre,open-label,randomised,phase 2 trial[J].Lancet Oncol,2020,21(1):162-174.
[4] 董梅,李依,张晓红.靶向冷冻消融术治疗局限性前列腺癌日间手术模式的应用[J].华西医学,2020,35(2):43-46.
[5] 李循,靳宏勇,张泽高,等.调强放疗联合内分泌治疗对前列腺癌患者免疫功能及EPIC评分的影响[J].癌症进展,2019,17(1):89-91.
[6] LODEIZEN O,DE BRUIN M,EGGENER S,et al.Ablation energies for focal treatment of prostate cancer[J].World J Urol,2019,37(3):409-418.
[7] SARGOS P,CHABAUD S,LATORZEFF I,et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy(GETUG-AFU 17):a randomised,phase 3 trial[J].Lancet Oncol,2020,21(10):1341-1352.
[8] CRAWFORD E D,HEIDENREICH A,LAWRENTSCHUK N,et al.Androgen-targeted therapy in men with prostate cancer:evolving practice and future considerations[J].Prostate Cancer Prostatic Dis,2019,22(1):24-38.
[9] 钱苏波,康健,沈海波,等.经直肠超声引导经皮冷冻消融治疗寡转移前列腺癌疗效的初步分析[J].临床泌尿外科杂志,2018,33(4):273-275.
[10] 李文亮,史沁兵,韩文华,等.调强放疗联合内分泌治疗前列腺癌的疗效及对患者免疫功能的影响[J].实用癌症杂志,2019,34(8):1275-1279.
[11] 时景伟,陈欢,崔蕊,等.前梯度蛋白2与血管内皮生长因子C在前列腺癌组织的表达及其临床意义[J].中华实验外科杂志,2018,35(4):785-786.
[12] BORST J,AHRENDS T,BABAŁA N,et al.CD4⁺ T cell help in cancer immunology and immunotherapy[J].Nat Rev Immunol,2018,18(10):635-647.
[13] 罗晓,卢红荪,李耀军,等.前列腺癌患者免疫功能及其与前列腺癌临床病理特点的关系[J].中华全科医学,2019,17(7):1118-1120.